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Background
Vesicular stomatitis virus (VSV) is a potent candidate
vaccine vector for various viral diseases (e.g. HIV, HCV,
RSV). The biggest limitation of VSV, however, is its
neurotoxicity, which limits application in humans. The
second drawback is that VSV induces neutralizing anti-
bodies rapidly and is thus ineffective as a vaccine vector
upon repeated applications. Our group has recently
shown that VSV pseudotyped with the glycoprotein
(GP) of the lymphocytic choriomeningitis virus (LCMV),
VSV-GP, is not neurotoxic. The aim of this project was
to evaluate the potential of VSV-GP as a vaccine vector.
Methods
For this purpose, we used Ovalbumin (OVA) as a model
antigen and analyzed immunogenicity of GP-pseudotyped
and wildtype VSV containing OVA (VSV-GP-OVA and
VSV-OVA) in vitro and in vivo in mouse models.
Results
We showed that both vectors infected murine bone
marrow-derived dendritic cells (bmDCs) in vitro. These
bmDCs were able to activate OVA specific CD8+ and
CD4+ T cells. Immunization experiments in mice
revealed that both VSV-OVA and VSV-GP-OVA
induced functional OVA-specific cytotoxic T cells
(CTLs) after a single immunization. In addition, with
both viruses, mice generated antibodies against OVA.
However, boosting with the same virus was only possi-
ble for the GP-pseudotyped virus but not for wild type
VSV. The efficacy of repeated immunization with
VSV-OVA was most likely limited by high levels of neu-
tralizing antibodies, which we detected after the first
immunization. In contrast, no neutralizing antibodies
against VSV-GP were induced even after boosting.
Conclusion
Taken together, we showed that the non-neurotoxic
VSV-GP is able to induce specific T cell and B cell
responses against the model antigen OVA to the same
level as the wild type VSV vector. However, in contrast
to wild type VSV, VSV-GP-OVA boosted the immune
response upon repeated applications. Thus, VSV-GP is a
promising novel vaccine vector.
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